|
1
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar
|
|
2
|
Cao H, Xu E, Liu H, Wan L and Lai M:
Epithelial-mesenchymal transition in colorectal cancer metastasis:
A system review. Pathol Res Pract. 211:557–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Panczyk M: Pharmacogenetics research on
chemotherapy resistance in colorectal cancer over the last 20
years. World J Gastroenterol. 20:9775–9827. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanz-Garcia E, Grasselli J, Argiles G,
Elez ME and Tabernero J: Current and advancing treatments for
metastatic colorectal cancer. Expert Opin Biol Ther. 16:93–110.
2016. View Article : Google Scholar
|
|
5
|
Sievers CK, Kratz JD, Zurbriggen LD,
LoConte NK, Lubner SJ, Uboha N, Mulkerin D, Matkowskyj KA and
Deming DA: The multidisciplinary management of colorectal cancer:
Present and future paradigms. Clin Colon Rectal Surg. 29:232–238.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ramesh M, Ahlawat P and Srinivas NR:
Irinotecan and its active metabolite, SN-38: Review of
bioanalytical methods and recent update from clinical pharmacology
perspectives. Biomed Chromatogr. 24:104–123. 2010. View Article : Google Scholar
|
|
8
|
Xu Y and Villalona-Calero MA: Irinotecan:
Mechanisms of tumor resistance and novel strategies for modulating
its activity. Ann Oncol. 13:1841–1851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu T, Li Z, Gao CY and Cho CH: Mechanisms
of drug resistance in colon cancer and its therapeutic strategies.
World J Gastroenterol. 22:6876–6889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zubeldia IG, Bleau AM, Redrado M, Serrano
D, Agliano A, Gil-Puig C, Vidal-Vanaclocha F, Lecanda J and Calvo
A: Epithelial to mesenchymal transition and cancer stem cell
phenotypes leading to liver metastasis are abrogated by the novel
TGFβ1-targeting peptides P17 and P144. Exp Cell Res. 319:12–22.
2013. View Article : Google Scholar
|
|
11
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitra A, Mishra L and Li S: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khan MA, Chen HC, Zhang D and Fu J: Twist:
A molecular target in cancer therapeutics. Tumour Biol.
34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu DJ, Chen XW, Zhang WJ, Wang JZ, Ouyang
MZ, Zhong Q and Liu CC: Twist1 is a potential prognostic marker for
colorectal cancer and associated with chemoresistance. Am J Cancer
Res. 5:2000–2011. 2015.PubMed/NCBI
|
|
16
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion, and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Niu RF, Zhang L, Xi GM, Wei XY, Yang Y,
Shi YR and Hao XS: Up-regulation of Twist induces angiogenesis and
correlates with metastasis in hepatocellular carcinoma. J Exp Clin
Cancer Res. 26:385–394. 2007.PubMed/NCBI
|
|
18
|
Ji H, Lu HW, Li YM, Lu L, Wang JL, Zhang
YF and Shang H: Twist promotes invasion and cisplatin resistance in
pancreatic cancer cells through growth differentiation factor 15.
Mol Med Rep. 12:3841–3848. 2015.PubMed/NCBI
|
|
19
|
Lee KW, Kim JH, Han S, Sung CO, Do IG, Ko
YH, Um SH and Kim SH: Twist1 is an independent prognostic factor of
esophageal squamous cell carcinoma and associated with its
epithelial-mesenchymal transition. Ann Surg Oncol. 19:326–335.
2012. View Article : Google Scholar
|
|
20
|
Chanmee T, Ontong P, Mochizuki N,
Kongtawelert P, Konno K and Itano N: Excessive hyaluronan
production promotes acquisition of cancer stem cell signatures
through the coordinated regulation of Twist and the transforming
growth factor β (TGF-β)-Snail signaling axis. J Biol Chem.
289:26038–26056. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J and Zhou BP: Activation of β-catenin
and Akt pathways by Twist are critical for the maintenance of EMT
associated cancer stem cell-like characters. BMC Cancer. 11:492011.
View Article : Google Scholar
|
|
22
|
Zhuo WL, Wang Y, Zhuo XL, Zhang YS and
Chen ZT: Short interfering RNA directed against TWIST, a novel zinc
finger transcription factor, increases A549 cell sensitivity to
cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res
Commun. 369:1098–1102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sakowicz-Burkiewicz M, Przybyla T,
Wesserling M, Bielarczyk H, Maciejewska I and Pawelczyk T:
Suppression of TWIST1 enhances the sensitivity of colon cancer
cells to 5-fluo-rouracil. Int J Biochem Cell Biol. 78:268–278.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stavrovskaya AA and Stromskaya TP:
Transport proteins of the ABC family and multidrug resistance of
tumor cells. Biochemistry (Mosc). 73:592–604. 2008. View Article : Google Scholar
|
|
25
|
Fletcher JI, Haber M, Henderson MJ and
Norris MD: ABC transporters in cancer: More than just drug efflux
pumps. Nat Rev Cancer. 10:147–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Johnatty SE, Beesley J, Paul J, Fereday S,
Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H, Harnett PR, et al
AOCS Study Group: ABCB1 (MDR 1) polymorphisms and progression-free
survival among women with ovarian cancer following
paclitaxel/carboplatin chemotherapy. Clin Cancer Res. 14:5594–5601.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu D, Lu Q and Hu X: Down-regulation of
P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by
honokiol. Cancer Lett. 243:274–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu K, Chen L, Han X and Wang J and Wang
J: Short hairpin RNA targeting Twist1 suppresses cell proliferation
and improves chemosensitivity to cisplatin in HeLa human cervical
cancer cells. Oncol Rep. 27:1027–1034. 2012.PubMed/NCBI
|
|
29
|
Lu S, Yu L, Mu Y, Ma J, Tian J, Xu W and
Wang H: Role and mechanism of Twist1 in modulating the
chemosensitivity of FaDu cells. Mol Med Rep. 10:53–60.
2014.PubMed/NCBI
|
|
30
|
Shen W, Pang H, Liu J, Zhou J, Zhang F and
Liu L, Ma N, Zhang N, Zhang H and Liu L: Epithelial-mesenchymal
transition contributes to docetaxel resistance in human non-small
cell lung cancer. Oncol Res. 22:47–55. 2014. View Article : Google Scholar
|
|
31
|
Biddle A and Mackenzie IC: Cancer stem
cells and EMT in carcinoma. Cancer Metastasis Rev. 31:285–293.
2012. View Article : Google Scholar
|
|
32
|
Ishiwata T: Cancer stem cells and
epithelial-mesenchymal transition: Novel therapeutic targets for
cancer. Pathol Int. 66:601–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liang L, Sun H, Zhang W, Zhang M, Yang X,
Kuang R and Zheng H: Meta-analysis of EMT datasets reveals
different types of EMT. PLoS One. 11:e01568392016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carnero A, Garcia-Mayea Y, Mir C, Lorente
J, Rubio IT and LLeonart ME: The cancer stem-cell signaling network
and resistance to therapy. Cancer Treat Rev. 49:25–36. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and
Li J: Cancer stem/progenitor cells are highly enriched in
CD133+CD44+ population in hepatocellular
carcinoma. Int J Cancer. 126:2067–2078. 2010. View Article : Google Scholar
|
|
36
|
Sahlberg SH, Spiegelberg D, Glimelius B,
Stenerlöw B and Nestor M: Evaluation of cancer stem cell markers
CD133, CD44, CD24: Association with AKT isoforms and radiation
resistance in colon cancer cells. PLoS One. 9:e946212014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: Prognostic significance of the cancer stem cell markers
CD133, CD44, and CD166 in colorectal cancer. Cancer Invest.
27:844–850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Elander N, Söderkvist P and Fransén K:
Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter
polymorphisms in colorectal cancer. Anticancer Res. 26(1B):
791–795. 2006.PubMed/NCBI
|
|
39
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Patterns of MMP-2 and MMP-9 expression in
human cancer cell lines. Oncol Rep. 21:1323–1333. 2009.PubMed/NCBI
|
